Longevity & chronic disease
Delaying and reversing age-related health decline and chronic disease.
Humanity is currently bound by the sky, rather than bound for it. Our mission at Skybound is to lift that constraint.
The absolute limiting factor for any sustained human presence in Low Earth Orbit and beyond is exactly that. Even with the best countermeasures we have at our disposal, this cascade of adverse physiological decline ultimately renders the human body operationally ineffective over time.
Mechanical unloading uncouples bone remodeling: osteoclastic resorption outpaces osteoblastic formation, and bone mineral density at the proximal femur and lumbar spine declines 1–2% per month — roughly an order of magnitude faster than postmenopausal osteoporosis — with hypercalciuria and nephrolithiasis as downstream sequelae. Concurrently, the antigravity musculature atrophies and undergoes a slow-to-fast fiber-type shift within weeks, while the deconditioned myocardium loses mass and stroke volume.
In the absence of gravitational sequestration, blood and cerebrospinal fluid redistribute cephalad, elevating intracranial and ocular venous pressure. Over a mission this produces posterior globe flattening, optic disc edema, choroidal folds, and a hyperopic refractive shift — Spaceflight-Associated Neuro-ocular Syndrome — accompanied by upward brain displacement and ventricular expansion that only partially normalize post-flight.
Microgravity and chronic mission stressors blunt T-cell activation and skew cytokine expression toward a dysregulated, pro-inflammatory phenotype. Latent herpesviruses — Epstein–Barr virus, cytomegalovirus, varicella-zoster — reactivate and shed asymptomatically, wound healing is impaired, and a persistent low-grade inflammatory state continues for the duration of the mission.
Beyond the geomagnetic shield, galactic cosmic radiation and solar particle events deposit high-LET energy that produces clustered, difficult-to-repair DNA double-strand breaks. The genotoxic burden accumulates with cumulative dose — raising lifetime carcinogenic risk and contributing to cardiovascular, central-nervous-system, and degenerative pathology that current shielding cannot fully mitigate.
Our ability to live and function for months or years without our bodies breaking down is a prerequisite for any serious vision of long-duration activity beyond Earth.
Lunar bases, Martian colonies, military outposts, large-scale manufacturing, and in-space commerce all depend on a level of physiological durability in space that we are currently unable to sustain.
The same physiological barriers that limit long-duration human presence in space have clear parallels with some of the largest and most difficult health problems on Earth. Skybound builds technologies precisely at that overlap.
Delaying and reversing age-related health decline and chronic disease.
Delivering advanced healthcare to anyone, anywhere, with minimal clinician supervision.
Personalized therapies that respond to the specific, real-time needs of the patient.
Skybound is developing a diverse portfolio of transformative platform medical technologies, organized around a self-sustaining engine of innovation.
A physiological barrier that becomes severe in space.
A platform technology that can intervene meaningfully in that barrier.
Drive down its technical and clinical risk.
Advance it toward commercialization across three theaters.
If technology can make the body more durable, more stable, and more supportable in the harsh environment of space, then those same technologies matter far beyond orbit.